One clinical trial found that participants regained about two-thirds of their previously lost weight within one year of stopping subcutaneous semaglutide.[10] Maintaining a relationship with a healthcare provider may help support long-term success by offering guidance, monitoring progress, and helping you build sustainable habits
Tirzepatide drug monograph
The primary pharmacodynamic distinctions between long-acting and short-acting GLP-1RAs are that long-acting agonists augment insulin production and suppress glucagon generation to lower postprandial glucose and fasting plasma glucose, while short-acting agonists chiefly lower postprandial glucose by delaying gastric emptying
Non-FDA approved compounded drugs claiming to contain semaglutide with high levels of known impurities and unknown impurities pose significant risks to patients and may lead to serious and life-threatening reactions, said Doug Langa, executive vice president of North America operations at Novo Nordisk
Which means the honest answer to "how much will I lose" is a range, not a number, and averages hide enormous spread
Both warrant Z79.85 for long-term injectable anti-hyperglycemic drug use when prescribed chronically, per FY2026 ICD-10-CM Guidelines
